Categories Health Care, Trending Stocks

One key stock you need to track ahead of COVID-19 vaccine approvals

Vaccine manufacturers have already seen a robust rally and have ventured into the overvalued zone. So it's time to look into the delivery space for wealth-building opportunities.

It’s been a spectacular year for many biotech and pharma investors who have made a killing out of the COVID-19 vaccine rally. Vaccine research specialists including Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO) have already seen gravity-defying stock movements this year. With Pfizer (NYSE: PFE) vaccine already approved in the UK and more approvals around the corner, it’s time investors look outside the biotech space for a pandemic-driven rally.

And that’s where McKesson Corporation (NYSE: MCK) comes into play. The company is the country’s largest distributor of pharmaceuticals and medical supplies through its extensive global network and using technology such as radio-frequency identification (RFID) tags and pharmacy robotics. The company also has a chain of independently-owned pharmacies under its network.

Why is this stock important?

Being assigned the centralized distributor for vaccine distribution by the government, McKesson will be responsible for the logistics and delivery of various vaccines to the administration centers in a timely and secured manner.

This is a huge responsibility and comes with its own set of risks and challenges. However, it may be noted that this is not the first time McKesson is handling such a task. The Irving, Texas-based company had delivered around 126 million doses of vaccine in 2010, during the H1N1 crisis.    

CFO Britt Vitalone had recently disclosed that the government would ultimately hold control over the distribution program, and there could be other players as well. He added that the operational approach would resemble what was seen a decade back with H1N1, though he declined from getting into more details.

McKesson Corp financials

Raised outlook

The management is pretty optimistic about the impact of vaccine distribution on the firm’s financials. When it reported the second-quarter earnings results last month, McKesson raised its outlook on the adjusted EPS for the fiscal year to $16.00 – $16.50, from the prior range of $14.70 – $15.50.

The company expects around 15-20 cents of this coming from the kitting and storage of ancillary supplies for the future COVID-19 vaccines.

Stock rally

The stock has gained 30% since the beginning of this year. Interestingly, much of this growth occurred by the end of October, when positive reports on the efficacy of various vaccines emerged.

And yet, the street continues to be bullish on the stock. The average 12-month price target on MCK is approximately 11% above the trading price on Friday.

Finally, the fact that McKesson has a decent history of paying dividends to its shareholders is another reason to keep it at least on the watchlist. The current dividend yield stands at 0.94% and the firm has raised its payout by around 13% annually over the past decade.


Is it time to book profits from Moderna? Find out.

Most Popular

MU Earnings: Micron’s Q4 profit declines but beats estimates

Micron Technology Inc. (NASDAQ: MU) Thursday said its fourth-quarter profit declined from last year, hurt by a sharp fall in revenues. Earnings, however, beat the market’s projection. On an adjusted

What are Philip Morris’ (PM) anticipations for the near term?

Shares of Philip Morris International Inc. (NYSE: PM) were down 1% on Thursday. The stock has dropped over 9% year-to-date. Although the tobacco industry has felt the pinch of inflation,

Key highlights from CarMax (KMX) Q2 2023 earnings results

CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,

Add Comment
Viewing Highlight